<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00833911</url>
  </required_header>
  <id_info>
    <org_study_id>MDT3-004</org_study_id>
    <nct_id>NCT00833911</nct_id>
  </id_info>
  <brief_title>An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee</brief_title>
  <official_title>An Open-Label Long-term Safety Study of Tramadol HCl OAD (Once A Day) 300 mg in the Treatment of Pain Due to Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labopharm Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labopharm Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect information regarding the long-term (6 and 12 months)
      safety of Tramadol HCl Once-A-Day(OAD) 300 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <primary_completion_date type="Actual">July 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Having Experienced an Adverse Event During the 6-12 Month Open-Label Safety Participation</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Spontaneous reports of adverse events were recorded for the entire study population, the 6-months safety population and the 12-months safety population</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">392</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Tramadol Contramid® OAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol Once A Day</intervention_name>
    <arm_group_label>Tramadol Contramid® OAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or Female patients between the ages of 40-75 with a diagnosis of Osteoarthritis
             of the knee consistent with the American College of Rheumatology (ACR) Clinical
             Classification Criteria for Arthritis of the Knee (Altman, R. et al., 1991):

               -  Current knee pain,

               -  Less than 30 minutes of morning stiffness with or without crepitus on active
                  motion,

               -  Confirmation either by arthroscopy or radiologist's report (X-rays showing
                  osteophytes, joint space narrowing or subchondral bone sclerosis {eburnation})
                  within two years prior to entry into the study.

          2. Erythrocyte Sedimentation Rate (ESR) &lt; 40 mm/hour.

          3. Western Ontario and McMaster Osteoarthritis Index (WOMAC) Pain Subscale total score of
             &gt;= 150 mm at baseline. (5 questions/100 mm scale each with an averaged response of 30
             mm or higher per question).

          4. Oral and written language comprehension at a level sufficient to comply with the
             protocol and complete study-related materials.

          5. The Patient has signed and dated the Research Ethics Board (REB) approved, written,
             informed consent prior to study participation.

        Exclusion Criteria:

          1. Known rheumatoid arthritis or any other rheumatoid disease.

          2. Secondary arthritis i.e. any of the following: septic arthritis; inflammatory joint
             disease; gout; pseudogout; Paget's disease; joint fracture; acromegaly; fibromyalgia;
             Wilson's disease; Ochronosis; Haemochromatosis; Osteochondromatosis; heritable
             arthritic disorders; or collagen gene mutations.

          3. Obesity Class II (Body Mass Index (BMI) &gt;= 35) (National Institutes of Health (NIH),
             2000).

          4. Major illness requiring hospitalization during the 3 months before commencement of the
             screening period.

          5. Patients who are unwilling to stop taking pain medication other than the study
             medication (for arthritis or other types of pain) or are unwilling to stop taking
             other medications for the treatment of osteoarthritis (OA).

          6. Patients who have previously failed tramadol hydrochloride (HCl) therapy or those who
             discontinued tramadol HCl due to adverse events.

          7. Patients who are taking or within the last 3 weeks have taken the following
             medications: monoamine oxidase inhibitors; tricyclic antidepressants and other
             tricyclic compounds (e.g. cyclobenzaprine, promethazine); neuroleptics; selective
             serotonin reuptake inhibitors; or other drugs which reduce seizure threshold.

          8. Patients who are taking or have taken another investigational agent within the last 30
             days.

          9. Patients with a history of seizure disorder other than Infantile Febrile Seizures.

         10. Patients who are opioid dependent.

         11. Patients with bowel disease causing malabsorption.

         12. Patients who are pregnant or lactating or patients of child-bearing potential who are
             unwilling to utilize a medically approved method of contraception during participation
             in this clinical trial.

         13. Patients with significant liver disease, defined as active hepatitis or elevated liver
             enzymes &gt;3 times the upper boundary of the normal range.

         14. Patients with significant renal disease, defined as creatinine clearance &lt;30 mL/min as
             estimated by the method of Levey et al., 1999.

         15. Current substance abuse or dependence, other than nicotine.

         16. Allergy or adverse reaction to tramadol or any structurally similar drugs e.g.
             opiates.

         17. Any other condition that, in the opinion of the investigators, would adversely affect
             the patient's ability to complete the study or its measures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=9048</url>
    <description>Approved labelling</description>
  </link>
  <results_reference>
    <citation>Mongin G. Tramadol extended-release formulations in the management of pain due to osteoarthritis. Expert Rev Neurother. 2007 Dec;7(12):1775-84. Review.</citation>
    <PMID>18052769</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2009</study_first_submitted>
  <study_first_submitted_qc>January 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2009</study_first_posted>
  <results_first_submitted>April 8, 2009</results_first_submitted>
  <results_first_submitted_qc>June 1, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 2, 2009</results_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to severe symptomatic osteoarthritis of the knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>300 mg Tramadol HCl OAD</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Titration</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="392"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="371"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Phase I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="371"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Phase II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="176">97 patients chose not to continue into Maintenance Phase II</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>300 mg Tramadol HCl OAD</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="392"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Having Experienced an Adverse Event During the 6-12 Month Open-Label Safety Participation</title>
        <description>Spontaneous reports of adverse events were recorded for the entire study population, the 6-months safety population and the 12-months safety population</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>All patients having taken 1 dose of 300 mg Tramadol HCl OAD at a minimum are being assessed for adverse event occurence for up to 12 months.
6-months safety: patients who completed at least 175 days on treatment.
12-months safety: patients who completed at least 350 days on treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients With 1 Dose of 300 mg Tramadol HCl OAD Minimum</title>
            <description>All patients in the study who took at least one dose of 300 mg Tramadol HCl OAD. Overall time frame for this population is 0-12 months.</description>
          </group>
          <group group_id="O2">
            <title>6-months Safety</title>
          </group>
          <group group_id="O3">
            <title>12-months Safety</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Having Experienced an Adverse Event During the 6-12 Month Open-Label Safety Participation</title>
          <description>Spontaneous reports of adverse events were recorded for the entire study population, the 6-months safety population and the 12-months safety population</description>
          <population>All patients having taken 1 dose of 300 mg Tramadol HCl OAD at a minimum are being assessed for adverse event occurence for up to 12 months.
6-months safety: patients who completed at least 175 days on treatment.
12-months safety: patients who completed at least 350 days on treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="392"/>
                <count group_id="O2" value="275"/>
                <count group_id="O3" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346"/>
                    <measurement group_id="O2" value="188"/>
                    <measurement group_id="O3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Patients With 1 Dose of 300 mg Tramadol HCl OAD Minimum</title>
          <description>All patients in the study who took at least one dose of 300 mg Tramadol HCl OAD. Overall time frame for this population is 0-12 months.</description>
        </group>
        <group group_id="E2">
          <title>6-months Safety</title>
        </group>
        <group group_id="E3">
          <title>12-months Safety</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="392"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="392"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="392"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="392"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis, Not Otherwise Specified (NOS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="392"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="392"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus, Not Otherwise Specified (NOS)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="392"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="392"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Osteoarthritis aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="392"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="392"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="392"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="392"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="275"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="321" subjects_at_risk="392"/>
                <counts group_id="E2" subjects_affected="169" subjects_at_risk="275"/>
                <counts group_id="E3" subjects_affected="101" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="38" subjects_affected="31" subjects_at_risk="392"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="275"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="155" subjects_affected="121" subjects_at_risk="392"/>
                <counts group_id="E2" events="86" subjects_affected="74" subjects_at_risk="275"/>
                <counts group_id="E3" events="51" subjects_affected="40" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="233" subjects_affected="159" subjects_at_risk="392"/>
                <counts group_id="E2" events="92" subjects_affected="62" subjects_at_risk="275"/>
                <counts group_id="E3" events="67" subjects_affected="42" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="67" subjects_affected="55" subjects_at_risk="392"/>
                <counts group_id="E2" events="24" subjects_affected="17" subjects_at_risk="275"/>
                <counts group_id="E3" events="17" subjects_affected="13" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="27" subjects_affected="19" subjects_at_risk="392"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="275"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="392"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="275"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="392"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="275"/>
                <counts group_id="E3" events="15" subjects_affected="13" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="392"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="275"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="392"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="275"/>
                <counts group_id="E3" events="11" subjects_affected="11" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="392"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="275"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="134" subjects_affected="106" subjects_at_risk="392"/>
                <counts group_id="E2" events="42" subjects_affected="30" subjects_at_risk="275"/>
                <counts group_id="E3" events="36" subjects_affected="22" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="80" subjects_affected="62" subjects_at_risk="392"/>
                <counts group_id="E2" events="31" subjects_affected="25" subjects_at_risk="275"/>
                <counts group_id="E3" events="42" subjects_affected="28" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="116" subjects_affected="99" subjects_at_risk="392"/>
                <counts group_id="E2" events="36" subjects_affected="29" subjects_at_risk="275"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="392"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="275"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="168"/>
              </event>
              <event>
                <sub_title>Sweating increased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="392"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="275"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="392"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="275"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="168"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to submitting results communications, the investigator shall allow Labopharm at least 30 days to review the proposed communication. If the proposed publication/disclosure risks Labopharm’s ability to patent any invention related to the study, the publication or disclosure will be modified or delayed to allow Labopharm to seek patent protection. This statement does not give Labopharm any editorial rights other than to restrict the disclosure of Labopharm’s confidential information.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Regulatory Affairs</name_or_title>
      <organization>Labopharm Inc.</organization>
      <phone>1 450 686 1017</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

